FDA Determines Regulatory Review Period for UBRELVY Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially approved the regulatory review period for UBRELVY, a human drug product, following a submission to the US Patent and Trademark Office (USPTO) for patent extension.